An Open-label, Single-arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-based Indices of Bone Formation and Resorption
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Abaloparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Radius Health Inc.
- 20 Aug 2018 New trial record
- 07 Aug 2018 Status changed from planning to recruiting, as reported in the Radius Health Inc. media release.